165 related articles for article (PubMed ID: 35633089)
1. Rapid, simple, and economical LC-MS/MS method for simultaneous determination of ceftazidime and avibactam in human plasma and its application in therapeutic drug monitoring.
Cheng Y; Chen M; Zhang B; Lin H; Li X; Cai Y; Zhang H; Que W; Liu M; Qiu H
J Clin Pharm Ther; 2022 Sep; 47(9):1426-1437. PubMed ID: 35633089
[TBL] [Abstract][Full Text] [Related]
2. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
Zhong H; Zhao XY; Zhang ZL; Gu ZC; Zhang C; Gao Y; Cui M
Int J Antimicrob Agents; 2018 Oct; 52(4):443-450. PubMed ID: 30012440
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
[TBL] [Abstract][Full Text] [Related]
5. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
6. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: A meta-analysis of randomised controlled trials.
Che H; Wang R; Wang J; Cai Y
Int J Antimicrob Agents; 2019 Dec; 54(6):809-813. PubMed ID: 31533075
[TBL] [Abstract][Full Text] [Related]
8. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
9. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
[TBL] [Abstract][Full Text] [Related]
11. Implementation of Chromatic Super CAZ/AVI
Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam.
Yang X; Wang D; Zhou Q; Nie F; Du H; Pang X; Fan Y; Bai T; Xu Y
BMC Microbiol; 2019 Nov; 19(1):240. PubMed ID: 31675928
[TBL] [Abstract][Full Text] [Related]
14. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
15. Resistance to ceftazidime-avibactam and underlying mechanisms.
Wang Y; Wang J; Wang R; Cai Y
J Glob Antimicrob Resist; 2020 Sep; 22():18-27. PubMed ID: 31863899
[TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
[TBL] [Abstract][Full Text] [Related]
17. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients.
Tsolaki V; Mantzarlis K; Mpakalis A; Malli E; Tsimpoukas F; Tsirogianni A; Papagiannitsis C; Zygoulis P; Papadonta ME; Petinaki E; Makris D; Zakynthinos E
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818820
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.
Xu C; Zeng F; Huang Y; Xu Q; Yang Y; Gong W; Shi C; Zhang Y
Int J Antimicrob Agents; 2024 Jan; 63(1):107021. PubMed ID: 37890733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
